Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.1173 | 0.3157 | 1 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0092 | 0 | 0.5 |
Onchocerca volvulus | 0.0092 | 0 | 0.5 | |
Schistosoma mansoni | Replicative DNA helicase | 0.0635 | 0.1588 | 1 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.3516 | 1 | 1 |
Mycobacterium tuberculosis | Probable replicative DNA helicase DnaB | 0.0635 | 0.1588 | 0.5031 |
Mycobacterium ulcerans | replicative DNA helicase DnaB | 0.0635 | 0.1588 | 0.5031 |
Leishmania major | pteridine reductase 1 | 0.0092 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0358 | 0.0777 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.1173 | 0.3157 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.1173 | 0.3157 | 1 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0092 | 0 | 0.5 |
Loa Loa (eye worm) | apoptosis regulator protein | 0.0358 | 0.0777 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.1173 | 0.3157 | 1 |
Treponema pallidum | replicative DNA helicase (dnaB) | 0.0635 | 0.1588 | 0.5 |
Brugia malayi | Apoptosis regulator proteins, Bcl-2 family protein | 0.0358 | 0.0777 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.1173 | 0.3157 | 1 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.1173 | 0.3157 | 1 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.1173 | 0.3157 | 0.5 |
Leishmania major | oxidoreductase-like protein | 0.0092 | 0 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.1173 | 0.3157 | 1 |
Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.1173 | 0.3157 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.